Company Overview and News

5
Finjan Holdings, Inc. (FNJN) CEO Philip Hartstein on Q2 2018 Results - Earnings Call Transcript

2018-08-05 seekingalpha - 1
Thank you for standing by. This is the conference operator. Welcome to the Finjan Holdings Second Quarter Shareholder Update Conference Call. As a reminder, all participants are in listen-only mode. And the conference is being recorded. After the presentation there will an opportunity to ask questions. [Operator Instructions]
4704 TMICF FNJN CBLK PANW TMICY ATYG

2
FNJN / Finjan Holdings, Inc. 8-K (Current Report)

2018-08-03 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FNJN

2
FNJN / Finjan Holdings, Inc. 8-K (Current Report)

2018-08-03 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FNJN

2
FNJN / Finjan Holdings, Inc. 10-Q (Quarterly Report)

2018-08-02 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FNJN

2
FNJN / Finjan Holdings, Inc. 8-K (Current Report)

2018-08-02 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FNJN

2
FNJN / Finjan Holdings, Inc. 8-K (Current Report)

2018-07-20 sec.gov
Document UNITED STATES
FNJN

3
Finjan Holdings to Host Shareholder Update Call on August 2, 2018

2018-07-18 globenewswire - 1
EAST PALO ALTO, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- Finjan Holdings, Inc. (NASDAQ:FNJN), a cybersecurity company, will host a shareholder update call to discuss its second quarter 2018 performance. The company will also broadly discuss its licensing pipeline along with potential future growth catalysts.
FNJN

6
FNJN / Finjan Holdings, Inc. 8-K (Current Report)

2018-07-10 sec.gov - 4
Document UNITED STATES
FNJN

6
Finjan and Trend Micro Enter into Confidential Patent License Agreement

2018-07-02 globenewswire - 1
EAST PALO ALTO, Calif. and SAN JOSE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Finjan Holdings, Inc. (NASDAQ:FNJN), and its subsidiaries, Finjan, Inc. (“Finjan”), Finjan Mobile, Inc. (“Finjan Mobile”), and Finjan Blue, Inc. (“Finjan Blue”), a pioneer in cybersecurity technologies, and Trend Micro Incorporated (TYO: 4704; TSE: 4704), a global leader in cybersecurity solutions, today announced that they had entered into an on-going license arrangement.
4704 TMICF FNJN TMICY

6
FNJN / Finjan Holdings, Inc. 8-K (Current Report)

2018-07-02 sec.gov - 1
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FNJN

11
FNJN / Finjan Holdings, Inc. 8-K (Current Report)

2018-06-25 sec.gov - 6
Document UNITED STATES
FNJN

7
My Investment Model Recommends THAT? What The...

2018-06-22 seekingalpha - 2
Sometimes it means you need to tweak the model, but often it's you rather than the model that needs adjustment.
FNJN

9
FNJN / Finjan Holdings, Inc. 8-K (Current Report)

2018-05-18 sec.gov - 4
Document UNITED STATES
FNJN

Related Articles

REPH: Recro Pharma Analysis and Research Report

23h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 31788H303